[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514700":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":16,"studyPopulation":42,"armGroups":43,"interventions":49,"overallOfficials":16,"centralContacts":54,"locations":60,"responsibleParty":78,"collaborators":82,"id":85,"slug":16,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":16,"enrollmentInfo":94,"targetDuration":16,"studyType":97,"phases":16,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":63,"whyStopped":16,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Asan Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"the composite event rate of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)","the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post procedure.\n\nA composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.","12 months",[14,18,20,22,24,26,28,30,33,35],{"measure":15,"description":16,"timeFrame":17},"the event rate of all cause death",null,"5 years",{"measure":19,"description":16,"timeFrame":17},"the event rate of cardiac death",{"measure":21,"description":16,"timeFrame":17},"the event rate of nonfatal myocardial infarction",{"measure":23,"description":16,"timeFrame":17},"the composite event rate of death, or nonfatal myocardial infarction (MI)",{"measure":25,"description":16,"timeFrame":17},"the composite event rate of cardiac death, or nonfatal myocardial infarction (MI)",{"measure":27,"description":16,"timeFrame":17},"the event rate of Target- Vessel Revascularization (TVR)",{"measure":29,"description":16,"timeFrame":17},"the event rate of Target- lesion Revascularization (TLR)",{"measure":31,"description":32,"timeFrame":17},"the event rate of stent thrombosis","according to an Academic Research Consortium (ARC) criteria",{"measure":34,"description":16,"timeFrame":17},"the event rate of stroke",{"measure":36,"description":37,"timeFrame":38},"the event rate of Procedural success","(defined as achievement of a final diameter stenosis of \\\u003C30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.","7 days",{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":40,"timePerspective":41,"maskingInfo":16},"COHORT","PROSPECTIVE","Patients receiving Xience-Skypoint™ stents.",[44],{"label":45,"type":16,"description":46,"interventionNames":47},"XIENCE Skypoint™ stent","Patients receiving Xience-Skypoint™ stents",[48],"Device: XIENCE Skypoint™ stent",[50],{"type":51,"name":45,"description":52,"armGroupLabels":53,"otherNames":16},"DEVICE","Percutaneous coronary intervention with Xience-Skypoint™ stent",[45],[55],{"name":56,"role":57,"phone":58,"phoneExt":16,"email":59},"Jung-hee Ham, Project manager","CONTACT","82230104728","cvcrc5@amc.seoul.kr",[61],{"facility":62,"status":63,"city":64,"state":16,"zip":16,"country":65,"countryCode":16,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Asan Medical Hospital","RECRUITING","Seoul","South Korea",{"type":67,"coordinates":68},"Point",[69,70],126.9784,37.566,{"lat":70,"lon":69},[73,76],{"name":74,"role":57,"phone":16,"phoneExt":16,"email":75},"Seung-jung Park, MD","sjpark@amc.seoul.kr",{"name":74,"role":77,"phone":16,"phoneExt":16,"email":16},"PRINCIPAL_INVESTIGATOR",{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"SPONSOR_INVESTIGATOR","Seung-Jung Park","Professor, Department of Cardiology, University of Ulsan College of Medicine",[83],{"name":84,"class":6},"CardioVascular Research Foundation, Korea","100514700",false,"NCT05981911","Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice","a Non-randomized, Prospective, Open-label Registry to Compare the Effectiveness and Safety of XIENCE Skypoint™ Stents Versus Other DESs in Patients With Coronary Artery Disease","IRIS Skypoint","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Xience-Skypoint™ stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other DESs\n2. Terminal illness with life expectancy \\\u003C1 year\n3. Patients with cardiogenic shock","ALL","19 Years",{"count":95,"type":96},2000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the effectiveness and safety of XIENCE Skypoint stents in comparison to other drug-eluting stents (DES) in real-world practice.",[100],"Coronary Artery Disease",[102,103],"drug eluting stent","Percutaneous Coronary Intervention","2025-12-28",{"date":106,"type":107},"2026-01-02","ACTUAL",{"date":109,"type":107},"2023-12-14",{"date":111,"type":96},"2026-12",{"name":80,"class":6},1]